Interactive Session:
1. Challenging Cases in Pediatric Infectious Diseases
Wednesday, October 2, 2013: 1:30 PM-3:30 PM
Room: The Moscone Center: 120-125
Co-organized with the American Academy of Pediatrics

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • analyze and formulate differential diagnoses and management plans for challenging cases
  • cite medical evidence and current expert opinion in management and prevention of infections
  • assess and compare knowledge anonymously with peers
  • identify unusual infectious diseases in children

Target Audience: public health practitioners, nurses, microbiologists, members-in-training, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID

Interactive Moderators:  Morven Edwards, MD, FIDSA, Baylor College of Medicine and Carol J. Baker, MD, FIDSA, FSHEA, Baylor College of Medicine


1:30 PM
Interactive Panelist
Anne Gershon, MD, FIDSA

1:50 PM
Interactive Panelist
B. Keith English, MD

2:10 PM
Interactive Panelist
Angela Myers, MD, MPH

2:30 PM
Interactive Panelist
Lorry Rubin, MD

CME Credits: Maximum of 2.0 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this session.

ACPE Number:


M. Edwards, Novartis Vaccines & Diagnostics: Consultant and Research Contractor, Consulting fee and Research grant

C. J. Baker, Novartis Vaccines & Diagnostics: Consultant, Consulting fee

A. Gershon, Merck: Consultant, funds to perfom molecular analyses of specimens and Research Contractor, Consulting fee, Fee for service and Research support
GSK: Consultant and DSMB Chair, Consulting fee and Payment for time spent, donated to Columbia University
Novartis: Consultant, Consulting fee

B. K. English, Cubist Pharmaceuticals: Grant Investigator, Grant recipient

A. Myers, None

L. Rubin, None

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.